Evaluating Combination Therapy in Community-Acquired Pneumonia [5]

Chest

Volumn 125, Issue 1, 2004, Pages 353-

  Powers, John H ^a,b   Cooper, Charles K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HFD 104 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HORMONE;

COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG SAFETY; HORMONE SUBSTITUTION; HUMAN; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT;

EID: 1642452867     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.1.353     Document Type: Letter

References (5)

1. Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims database. Chest 2003; 123:1503-1511
2. Waterer GW. Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire? Chest 2003; 123:1328-1329
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333
4. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i. v.) and oral moxifloxacin compared with sequential i. v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746-1754
5. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965-1972